Literature DB >> 9824500

Involvement of c-myc in the resistance of non-obese diabetic mice to glucocorticoid-induced apoptosis.

T C Martins1, A P Aguas.   

Abstract

Non-obese diabetic (NOD) mice spontaneously develop insulin-dependent diabetes mellitus (IDDM) as a consequence of autoimmune aggression of beta cells of the endocrine pancreas by T cells. T lymphocytes of NOD mice are resistant to apoptosis induced by glucocorticoids, or by starving or DNA-damaging treatments, a feature that was interpreted as being linked to escape of autoreactive T cells from thymic negative selection. c-myc is one of the gene targets of glucocorticoids (GC), its expression being down-regulated by the activated GC-GC receptor complex. We investigated here whether expression of Myc protein, in response to dexamethasone stimulation, was the same in NOD mice and in non-autoimmune strains, namely NON, BALB/c and C57Bl.6. We found a consistent increase in the levels of Myc protein after GC-treatment of lymphocytes of NOD mice, a finding that was in contrast to the down-regulation of c-myc that we observed in lymphocytes from mice not prone to diabetes. We also report that, rather than a absolute resistance to GC-induced cell death, NOD mice display a delayed apoptotic response to GC. We propose that the resistance of NOD mice lymphocytes to GC-induced apoptosis is because of inhibition of the repressive action of GC-GR complexes at the level of c-myc transcription. This deficient action of GC-GR results in increased production of nuclear Myc protein, peculiar to NOD mice cells, following their treatment with GC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824500      PMCID: PMC1364403          DOI: 10.1046/j.1365-2567.1998.00600.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

Review 1.  Physiological T-cell death: susceptibility is modulated by activation, aging, and transformation, but the mechanism is constant.

Authors:  D S Ucker; L D Hebshi; J F Blomquist; B E Torbett
Journal:  Immunol Rev       Date:  1994-12       Impact factor: 12.988

Review 2.  Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry.

Authors:  W G Telford; L E King; P J Fraker
Journal:  J Immunol Methods       Date:  1994-06-03       Impact factor: 2.303

Review 3.  Apoptosis and steroid hormones.

Authors:  E B Thompson
Journal:  Mol Endocrinol       Date:  1994-06

Review 4.  Regulation of apoptosis in the immune system.

Authors:  P H Krammer; I Behrmann; P Daniel; J Dhein; K M Debatin
Journal:  Curr Opin Immunol       Date:  1994-04       Impact factor: 7.486

5.  Genetic analysis of immune dysfunction in non-obese diabetic (NOD) mice: mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T cells to apoptosis induction.

Authors:  H J Garchon; J J Luan; L Eloy; P Bédossa; J F Bach
Journal:  Eur J Immunol       Date:  1994-02       Impact factor: 5.532

6.  Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line.

Authors:  J Kiefer; S Okret; M Jondal; D J McConkey
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

7.  c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation.

Authors:  K Rhee; W Bresnahan; A Hirai; M Hirai; E A Thompson
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

8.  Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor.

Authors:  A Helmberg; N Auphan; C Caelles; M Karin
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

9.  A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1.

Authors:  S Heck; M Kullmann; A Gast; H Ponta; H J Rahmsdorf; P Herrlich; A C Cato
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

10.  Lymphoma models for B cell activation and tolerance. X. Anti-mu-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc.

Authors:  G Fischer; S C Kent; L Joseph; D R Green; D W Scott
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Hormonal regulation of physiological cell turnover and apoptosis.

Authors:  R D Medh; E B Thompson
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

2.  Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells.

Authors:  R D Medh; A Wang; F Zhou; E B Thompson
Journal:  Oncogene       Date:  2001-08-02       Impact factor: 9.867

3.  Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse.

Authors:  LaTayia M Aaron-Brooks; Takeshi Sasaki; Renee E Vickman; Lin Wei; Omar E Franco; Yuan Ji; Susan E Crawford; Simon W Hayward
Journal:  Prostate       Date:  2019-04-18       Impact factor: 4.104

4.  Alterations of renal phenotype and gene expression profiles due to protein overload in NOD-related mouse strains.

Authors:  Karen H S Wilson; Richard A McIndoe; Sarah Eckenrode; Laurence Morel; Anupam Agarwal; Byron P Croker; Jin-Xiong She
Journal:  BMC Nephrol       Date:  2005-12-21       Impact factor: 2.388

5.  Hepatocarcinogenic potential of the glucocorticoid antagonist RU486 in B6C3F1 mice: effect on apoptosis, expression of oncogenes and the tumor suppressor gene p53.

Authors:  Jihan A Youssef; Mostafa Z Badr
Journal:  Mol Cancer       Date:  2003-01-03       Impact factor: 27.401

6.  Molecular phenotyping of immune cells from young NOD mice reveals abnormal metabolic pathways in the early induction phase of autoimmune diabetes.

Authors:  Jian Wu; Dorothy N Kakoola; Nataliya I Lenchik; Dominic M Desiderio; Dana R Marshall; Ivan C Gerling
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.